Loading clinical trials...
Loading clinical trials...
A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies
Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Gabrail Cancer Center Research
Canton, Ohio, United States
Gettysburg Cancer Center
Gettysburg, Pennsylvania, United States
Start Mountain Region
West Valley City, Utah, United States
Hight Technology Hospital Medcenter
Batumi, Georgia
K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia
Simon Khechinashvili University Hospital
Tbilisi, Georgia
Barcelona HM Nou Delfos
Barcelona, Spain
Madrid - FJD
Madrid, Spain
START CIOCC Hospital HM Sanchinarro
Madrid, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Start Date
July 20, 2021
Primary Completion Date
March 8, 2023
Completion Date
February 29, 2024
Last Updated
July 28, 2025
35
ACTUAL participants
Pelabresib
DRUG
Lead Sponsor
Constellation Pharmaceuticals
NCT05720117
NCT06898450
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06658951